Short-Acting Insulin Market Research Explores Growth Within A $14.87 Billion Opportunity

The market for short-acting insulin has shown robust expansion recently, driven by a growing population of diabetes patients and improved treatment options. As healthcare continues to evolve, this sector is expected to experience sustained growth, supported by advancements in insulin delivery and management strategies. Let's explore the current market size, key drivers, major players, emerging trends, and segmentation details shaping this important healthcare segment.

Forecasted Market Size and Growth Trajectory of the Short-Acting Insulin Market
The short-acting insulin market has experienced solid growth in recent years. It is projected to increase from $11.54 billion in 2025 to $12.14 billion in 2026, growing at a compound annual growth rate (CAGR) of 5.3%. This upward trend during the historical period is linked to the high prevalence of diabetes globally, widespread use of insulin therapies, increasing hospital-based diabetes management, expanded access programs for insulin, and better diagnosis rates for the condition.

Download a free sample of the short-acting insulin market report:
https://thebusinessresearchcompany.com/sample_request?id=79113975&type=smp&name=Short-Acting%20Insulin%20Market%20Report%202026&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

Looking ahead, the market is expected to continue its strong growth momentum, reaching $14.87 billion by 2030 at a CAGR of 5.2%. Factors contributing to this growth include the rising incidence of type 2 diabetes, greater dependence on insulin treatments, the expansion of home-based diabetes care services, advances in insulin delivery technologies, and heightened demand for fast-acting insulin products. Key developments anticipated in this period involve increased focus on controlling post-meal blood glucose levels, broader use of rapid-acting insulin analogues, growth in pre-filled insulin pen adoption, expansion of intensive insulin therapy protocols, and a stronger emphasis on tight glycemic control.

Leading Companies Influencing the Short-Acting Insulin Market Landscape
Several major pharmaceutical companies play a dominant role in the short-acting insulin market, including Sanofi S.A., Eli Lilly and Company, Novo Nordisk A/S, Biocon Limited, Lupin Limited, Wockhardt Ltd., Julphar (Gulf Pharmaceutical Industries), Geropharm LLC, Bioton S.A., Gan & Lee Pharmaceuticals Co. Ltd., Lannett Company Inc., MannKind Corporation, ADOCIA S.A.S., Baxter International Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., United Laboratories International Holdings Ltd., Bharat Biotech International Ltd., Shanghai Fosun Pharmaceutical Group Co. Ltd., Dongbao Enterprise Group Co. Ltd., and Aspen Pharmacare Holdings Limited.

View the full short-acting insulin market report:
https://www.thebusinessresearchcompany.com/report/short-acting-insulin-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Oct_PR

A significant recent development occurred in December 2024 when Lupin Limited, an Indian pharmaceutical company, acquired the Humulin insulin range in India from Eli Lilly & Company for an undisclosed sum. This acquisition enables Lupin to enhance its foothold in the Indian insulin market by adding the Huminsulin portfolio from Eli Lilly. Eli Lilly, headquartered in the United States, is well-known for its specialization in insulin products, including short-acting insulin varieties.

Innovative Trends Reshaping the Short-Acting Insulin Market
Key players in the short-acting insulin industry are increasingly focusing on developing interchangeable rapid-acting insulin biologics aimed at improving glycemic control and offering patients greater flexibility. These biologics are designed to act quickly in lowering blood sugar following meals and have regulatory approval to be substituted for equivalent insulin products without requiring a new prescription. This approach supports consistent diabetes management while enhancing patient convenience.

For example, in July 2025, Biocon Biologics, a biosimilars company with operations in India and the United States, received FDA approval for Kirsty (insulin aspart xjhz). Kirsty is the first and only interchangeable rapid-acting insulin aspart approved in the U.S. and serves as a biosimilar to NovoLog (insulin aspart). Clinical and analytical evidence confirmed no notable differences in safety, efficacy, purity, and potency between Kirsty and NovoLog. The product is available in a 100 units/mL formulation, offered both as a single-patient-use prefilled pen for subcutaneous injection and as a multi-dose vial suitable for subcutaneous and intravenous administration. This innovation aims to enhance glycemic control for both adult and pediatric diabetes patients.

Comprehensive Segmentation of the Short-Acting Insulin Market
This market is categorized based on several key parameters:

1) Formulation Types:
- Regular Insulin
- Rapid-Acting Insulin

2) Dosage Forms:
- Vials
- Pre-filled Pens
- Cartridges

3) Administration Routes:
- Subcutaneous
- Intravenous

4) Patient Types:
- Type 1 Diabetes
- Type 2 Diabetes

5) Distribution Channels:
- Pharmacies
- Hospital Pharmacies
- Online Pharmacies

Further subsegments include:
- Under Regular Insulin: Human Regular Insulin, Animal-Derived Regular Insulin, and Other Regular Insulin
- Under Rapid-Acting Insulin: Insulin Lispro, Insulin Aspart, and Insulin Glulisine

This detailed breakdown helps stakeholders understand the market dynamics and tailor strategies to meet specific patient and healthcare provider needs.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.